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Chemokines comprise a class of structurally related
proteins that are involved in many aspects of leukocyte
migration under basal and inflammatory conditions. In
addition to the large number of genes, limited process-
ing of these proteins by a variety of enzymes enhances
the complexity of the total spectrum of chemokine vari-
ants. We have recently shown that the native chemokine
CXCL10 is processed at the C terminus, thereby shed-
ding the last four amino acids. The present study was
performed to elucidate the mechanism in vivo and in
vitro and to study the biological activity of this novel
isoform of CXCL10. Using a combination of protein pu-
rification and mass spectrometric techniques, we show
that the production of C-terminally truncated CXCL10
by primary keratinocytes is inhibited in vivo by a spe-
cific inhibitor of pro-protein convertases (e.g. furin) but
not by inhibition of matrix metalloproteinases. More-
over, CXCL10 is processed by furin in vitro, which is
abrogated by a mutation in the furin recognition site.
Using GTPS binding, Ca2 mobilization, and chemo-
taxis assays, we demonstrate that the C-terminally trun-
cated CXCL10 variant is a potent ligand for CXCR3.
Moreover, the inverse agonist activity on the virally
encoded receptor ORF74 and the direct antibacterial
activity of CXCL10 are fully retained. Hence, we have
identified furin as a novel chemokine-modifying enzyme
in vitro and most probably also in vivo, generating a
C-terminally truncated CXCL10, which fully retains its
(inverse) agonistic properties.
Chemokines comprise a class of structurally related proteins
that are involved in many aspects of leukocyte migration under
basal and inflammatory conditions (1). Their action is primar-
ily achieved through ligand-specific activation of seven trans-
membrane G-protein-coupled receptors expressed on target
cells.
In addition to the large number of genes encoding chemo-
kines, processing of these proteins by (a limited number of)
enzymes increases the complexity of chemokine signaling. Be-
sides the large body of evidence on chemokine processing by
dipeptidylpeptidase IV (CD26) (2), several novel chemokine
processing enzymes have been identified in the past few years,
e.g. matrix metalloproteinase 2 and 9, cathepsin D and G, and
elastase (3–8). Apart from a range of biological effects on che-
mokine receptor activation, processed chemokines occasionally
gain very unexpected, sometimes not even chemokine receptor-
related, activities (9, 10).
In general, alterations at the N terminus down-regulate che-
mokine receptor potencies and are therefore considered impor-
tant mechanisms to modulate inflammatory responses. Several
naturally occurring truncations of chemokines have been iden-
tified from which it is still unknown which system is involved
in their formation. Interestingly, several of these represent
C-terminal truncations, as in the case of CXCL7 (11, 12) and
CCL20 (13). One specific C-terminal truncation of CXCL7,
found in platelets, involves the removal of the last two amino
acids. In contrast to intact CXCL7, this form has potent anti-
bacterial activity (10), pointing to a role central role of the
C-terminal amino acids in the innate immune activity of this
chemokine.
For the chemokine receptor CXCR3 three ligands are known
(CXCL9, -10, and -11). The CXCR3 receptor is highly expressed
on activated T-lymphocytes and CXCR3 T-cells have been
implicated in several pathological conditions. For example,
CXCR3 and its ligands are involved in allograft rejection (14,
15), wound healing, and angiogenesis (16). In the skin, expres-
sion of CXCR3 targeting chemokines by keratinocytes, fibro-
blasts, and endothelial cells contributes to the influx of T-
lymphocytes (17, 18). A recent study has shown that the
CXCR3 ligands also possess direct antibacterial activity (19),
suggesting a role for these chemokines in the innate immune
response.
All three CXCR3 ligands are sensitive to N-terminal trunca-
tion by dipeptidylpeptidase IV (20, 21). In addition, we have
recently shown that native CXCL10 that is produced upon
stimulation of primary human keratinocytes with interferon-
is partially processed to a CXCL10 molecule that lacks the last
four C-terminal amino acids (22). The aim of the present study
was to identify the enzymatic system responsible for the in vivo
cleavage of CXCL10 and to determine the biological activity of
this novel CXCL10 variant using several different biological
assays. We demonstrate that furin can cleave CXCL10 in vitro
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and that an inhibitor of pro-protein convertases (e.g. furin)
prevents processing of CXCL10 in vivo. We therefore identify
furin as a novel chemokine-processing enzyme. The resulting
CXCL10 variant retains full (inverse) agonistic activities.
EXPERIMENTAL PROCEDURES
Materials—Human CXCL9, -10, and -11 and murine CXCL10 were
obtained from R&D Systems Inc. (Minneapolis, MN). Human CXCL11
and CXCL10 were obtained from Peprotech (Rocky Hill, NJ). Purified
furin and the pro-protein convertase inhibitor decanoyl-RVKR-chlorom-
ethylketone were purchased from Alexis (Lausen, Switzerland). Porcine
pancreas carboxypeptidase B was obtained from Calbiochem (San
Diego, CA). Recombinant human IFN-1 and TNF- were from Strath-
mann Biotech GmbH (Hannover, Germany). Poros 50 R2 was obtained
from Applied Biosystems (Foster City, CA). DEAE-dextran (chloride
form) was obtained from Sigma. Dulbecco’s modified Eagle’s medium
(DMEM) was obtained from Invitrogen, fetal bovine serum was pur-
chased from Integro B. V. (Dieren, The Netherlands) and penicillin-
streptomycin was from BioWhittaker Europe (Verviers, Belgium). pNF-
B-Luc was obtained from Stratagene (La Jolla, CA.)
Cell Culturing and Stimulation—Keratinocytes were obtained from
human foreskin and grown in single cell suspensions in low calcium (0.1
mM) serum-free medium (keratinocyte-SFM, Invitrogen) as described
earlier (22). The culture of primary human dermal fibroblasts was
established as described earlier (23).
To induce chemokine expression, cells were stimulated with 2000
units/ml human rIFN- (keratinocytes) or 500 units/ml human rIFN- 
500 units/ml human rTNF (fibroblasts), for 6 h. Following this stim-
ulation, cells were washed with phosphate-buffered saline and trans-
ferred to MCDB153 medium (Invitrogen) and allowed to secrete che-
mokines for 18 h at 37 °C.
Application of Proteinase Inhibitors in Keratinocyte Cultures—Hu-
man keratinocytes were cultured and stimulated as described above.
After stimulation and washing of the cells, keratinocyte-derived che-
mokines were produced in the presence of either 25 M decanoyl-RVKR-
chloromethylketone or 20 g/ml Marimastat.
Purification of CXCR3-targeting Chemokines—Supernatants from
chemokine expressing cells were filtered through a 0.22-m filter and
applied to a 1-ml HiTrap heparin column (Amersham Biosciences)
equilibrated with 10 mM sodium phosphate, pH 7.1. The column was
subsequently washed with 5 ml of 10 mM sodium phosphate (pH 7.1)
containing 0.35 M NaCl. This was followed by elution of heparin-binding
proteins using 2 ml of 1.5 M NaCl in 10 mM phosphate (pH 7.1).
Chemokines were further purified using reverse phase high-perfor-
mance liquid chromatography (HPLC) on a 2.1  250 mm Nucleosil
C-18 column (Machery-Nagel, Du¨ren, Germany) with a flow rate of 0.3
ml/min. Proteins were eluted using a continuous gradient from 0 to 60%
acetonitrile (in 0.02% HCl) over 60 min and collecting 1-min fractions.
In Vitro Processing and Mass Spectrometric Analysis of Chemo-
kines—Recombinant chemokines at a concentration of 2 M were incu-
bated with furin (5 units/ml) alone, or in combination with carboxypep-
tidase B (0.5 units/ml) in a buffer containing 100 mM HEPES and 1 mM
CaCl2 (pH 7.6) at 37 °C for 3 h.
To establish the time course of furin-mediated cleavage of human
CXCL10, recombinant CXCL10 (0.5 M) was incubated with 0.1 units of
furin in 20 l of 100 mM HEPES and 1 mM CaCl2, pH 7.6, for 0, 0.5, 1,
5, 30, and 60 min at 37 °C.
After digestion, chemokines were desalted using Poros 50 R2, packed
in a pipette tip. Peptides were eluted in 60% acetonitril/0.02% HCl and
measured by MALDI-MS (Reflex, Bruker Daltonics, Bremen) using
dihydroxybenzoic acid as a matrix.
To determine kinetic parameters of CXCL10 conversion by furin,
different concentrations of CXCL10 were incubated with 0.1 units of
furin and incubated for 15 min. The ratio of the abundance of the intact
and the cleaved forms was measured by MALDI-MS and used to calcu-
late the amount of substrate converted. Data were subsequently fitted
to the Michaelis-Menten equation.
For large scale production of C-terminally truncated CXCL10, in
vitro digestions were carried out using 25 g recombinant CXCL10
using 10 units of furin in combination with 0.3 units of carboxypepti-
dase B, and used this material in several bioassays. As a control, intact
recombinant CXCL10 was treated identically, though without the
enzymes.
GTPS Binding—CXCR3-expressing CHO cells (24) were scraped in
their medium, pelleted, and resuspended in GTPS binding buffer (20
mM HEPES, 100 mM NaCl, 5 mM MgCl2, 0.1% bovine serum albumin,
pH 7.4), containing 1 mM EDTA. Cells were kept on ice for 20 min and
subsequently sonicated (2  15 s, with 2-min interval). Large cellular
debris was removed by centrifugation at 200  g. Cell membranes were
pelleted from the supernatant at 48,000 g and resuspended in GTPS
binding buffer and incubated (1 g) for 20 min at 30 °C with 1 M GDP
in a total volume of 200 l. Following incubation with various concen-
trations of chemokines for 10 min at 30 °C, membranes were incubated
with 0.3 nM [35S]GTPS (1250 Ci/mmol, PerkinElmer) for 20 min at
30 °C. The reaction was terminated by filtering the membranes through
a GF/B filter (Whatman) using ice-cold buffer (20 mM HEPES, 10 mM
sodium pyrophosphate (Na4P2O7), pH 7.4). Filters were transferred to
counting vials and membrane-bound [35S]GTPS was measured by
liquid scintillation in a Wallac 1410.
Ca2 Mobilization—Intracellular calcium mobilization was meas-
ured as described previously (24). In brief, CHO cells stably transfected
with human CXCR3 were loaded with 1 mM Fura-2 acetoxymethyl
esther (Molecular Probes, Leiden, The Netherlands). Upon receptor
stimulation, fluorescence recordings were made in a continuously
stirred 1-ml cuvette at 37 °C using a fluorescence spectrophotometer
(Photon Technology International, Inc., Lawrenceville, NJ).
Chemotaxis—Human peripheral blood T-cells were isolated from
buffy coats of healthy donors and stimulated with IL-2 (100 units/ml)
and PHA (1 mg/ml) to induce CXCR3 expression, as described previ-
ously (24). Chemotaxis of these cells toward chemokines was studied
using a Transwell assay starting with 5  106 cells/100 l for each
individual assay.
ORF74 Constitutive Activity—The cDNA of HHV-8-encoded ORF74
(GenBankTM accession number U71368 with a silent G-to-T mutation
at position 927 (a gift from Dr. T. W. Schwartz)) was inserted into
pcDEF3 (A gift from Dr. J. A. Langen) after PCR amplification. COS-7
cells were grown at 5% CO2 and 37 °C in Dulbecco’s modified Eagle’s
medium supplemented with 5% fetal bovine serum, 50 units/ml peni-
cillin and 50 g/ml streptomycin. COS-7 cells were transiently cotrans-
fected with pcDEF3-ORF74 or pcDEF3 (mock) and pNF-B-Luc using
the DEAE-dextran method. After transfection, cells were seeded in
96-well white plates (Costar, Corning, NY) in serum-free culture me-
dium in the presence of indicated ligands. 48 h after transfection, cells
were assayed for NF-B-driven luciferase expression. Luminescence
was measured in a Wallac Victor (PerkinElmer).
Antibacterial Activity—Radial diffusion assays (RDAs) were per-
formed as previously described (19), using Escherichia coli ATCC 054
and Listeria monocytogenes EGD. The underlay consisted of 1% agarose
and 1:100 dilution of trypticase soy broth in 10 mM sodium phosphate,
pH 7.4, containing 1  106 bacteria. Within the solidified agarose, a
series of 3-mm diameter wells were punched and 5 l of chemokines
were added. Plates were incubated for 3 h at 37 °C to allow peptide
diffusion. The underlay was then covered with overlay (6% trypticase
soy broth agar and 1% agarose in H2O), and the plates were allowed
to solidify. Antimicrobial activity was determined as a clear zone
around the well after 16-h incubation at 37 °C, and are represented in
radial diffusion units: (diameter of clear zone in millimeters  well
diameter)  10.
RESULTS
Production of CXCL10 by IFN--stimulated Primary Human
Keratinocytes—We have previously shown that stimulation of
human keratinocytes with IFN- induces the production of the
CXCR3 targeting chemokines CXCL9, -10, and -11 (24). Fol-
lowing heparin affinity chromatography these chemokines can
be purified by reversed-phase chromatography (Fig. 1A). Inter-
estingly, upon mass spectrometric analysis of HPLC-purified
keratinocyte-derived CXCL10, we found two different mole-
cules of CXCL10, one complete form (1–77) and a C-terminally
truncated form (1–73) that lacks the last four amino acids
Lys-Arg-Ser-Pro (Fig. 1B).
The sequence -Lys70-Glu-Arg-Ser-Lys-Arg-Ser-Pro77 (KER-
SKRSP) found in the C-terminal part of human CXCL10 con-
tains a consensus sequence (Arg-Xaa-(Lys/Arg)-Arg-Xaa) for
the pro-protein convertase furin. This tempted us to speculate
that human CXCL10 is processed in vivo by furin convertase.
1 The abbreviations used are: IFN-, interferon , CHO, Chinese
hamster ovary; GTPS, guanosine 5-3-O-(thio)triphosphate; ORF,
open reading frame; TNF, tumor necrosis factor; PC, pro-protein
convertases.
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In analogy with other systems (e.g. insulin and neuropeptides),
additional trimming to serine by a carboxypeptidase would
yield fully processed CXCL10-(1–73).
To explore the possibility that CXCL10 is processed by such
a system, we first treated IFN--stimulated keratinocytes with
the cell permeable pro-protein convertase inhibitor decanoyl-
RVKR-chloromethylketone and determined the form of
CXCL10 produced by these cells. As predicted, the production
of CXCL10-(1–73) was almost completely inhibited by decano-
yl-RVKR-chloromethylketone (Fig. 1C).
It has recently been shown that several chemokines are
substrates for matrix metalloproteinases (MMP) (3, 25). Sev-
eral of these MMPs are activated upon cleavage by furin (26).
This raised the possibility that inhibition of furin could have
indirectly inhibited the production of CXCL10-(1–73) by pre-
venting activation of MMPs. We therefore also treated IFN--
stimulated keratinocytes with the broad range MMP inhibitor
Marimastat (20 g/ml). This treatment did not have any effect
on the relative amounts of CXCL10-(1–77) and CXCL10-(1–73)
that were produced by these cells (Fig. 1D).
To exclude the possibility that the appearance of CXCL10-
(1–73) in the medium of IFN- stimulated keratinocytes was an
artifact of culturing conditions, we also cultured keratinocytes
in medium (Defined SFM, Invitrogen) that did not contain
bovine pituitary extract. After stimulation with IFN- these
cells produced similar amounts of CXCL10-(1–73) as shown in
Fig. 1B.
In Vitro Cleavage of Human CXCL10 with Furin and Car-
boxypeptidase B—To directly demonstrate that human CXCL10
is a substrate for furin, we performed in vitro digestions with
commercially available human CXCL10. This CXCL10 contains
an extra N-terminal methionine (Met-CXCL10-(1–78)). We
first treated a 2 M solution of Met-CXCL10-(1–78) with 5
units/ml of furin at 37 °C for 3 h and compared this with
CXCL10 left at 37 °C without furin. The mass of Met-CXCL10-
(1–78) is 8773 Da (Fig. 2A, Table I). After treatment with furin,
the mass of the recombinant CXCL10 shifted to 8589 Da (Fig.
2B, Table I). This matches with a Met-CXCL10-(1–76) molecule
lacking the last two amino acids Ser-Pro, resulting from cleav-
age after the dibasic sequence Lys-Arg preceding these two
C-terminal amino acids. This is exactly as would be expected
from furin-mediated cleavage of CXCL10. Upon treatment of
the furin processed CXCL10 with the basic specific carboxypep-
tidase B in vitro (0.5 units/ml), this molecule was further pro-
cessed to Met-CXCL10-(1–74) with a mass of 8305 Da (Fig. 2C).
This matches with the removal of the basic amino acids Lys-
Arg, the two C-terminal amino acids of CXCL10 after treat-
ment with furin (Table I). Intact human CXCL10 was insensi-
FIG. 1. Influence of protease inhibi-
tors on the production of different
CXCL10 variants by primary human
keratinocytes. Primary human kerati-
nocytes were stimulated with IFN (2000
units/ml) and allowed to excrete chemo-
kines for 16 h. Following heparin affinity
chromatography of the culture medium,
CXCR3 targeting chemokines were puri-
fied using reversed phase chromatogra-
phy (A). MALDI-MS was used to charac-
terize the CXCL10 variants produced by
keratinocytes cultured without inhibitor
(B), treated with the pro-protein conver-
tase inhibitor dec-RVKR-cmk (C) and the
matrix metalloproteinase inhibitor mari-
mastat (D).
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tive to treatment by carboxypeptidase B alone (data not
shown). Altogether, these data show that sequential treatment
of CXCL10 with furin followed by a basic specific carboxypep-
tidase results in the formation of CXCL10 lacking the last four
amino acids.
Kinetics of Furin-mediated Cleavage of Human CXCL10—To
determine the time dependence of the furin-mediated cleavage
of human Met-CXCL10 in vitro, 0.5 M solutions of human
Met-CXCL10 were incubated with 5 units/ml of furin at 37 °C
for different periods of time. MALDI-MS was used to determine
the relative amount of Met-CXCL10-(1–78) and Met-CXCL10-
(1–76). As can be seen in Fig. 3A, cleavage was completed
within 1 h of incubation with furin. In addition, the concentra-
tion dependence of the conversion rate of CXCL10 was deter-
mined (Fig. 3B). This analysis revealed a Km of 5 M.
A Mutation in the Furin Consensus Site Prevents Cleavage of
Human CXCL10—A cDNA encoding the human CXCL10 pro-
tein has long been used as a template for production of human
CXCL10 protein (27). This predicted protein, however, differs
from that identified on the basis of mass spectrometric analysis
of the native protein (22), because it contains a methionine at
position 72 instead of an arginine (CXCL10 R72M). A commer-
cially available variant of recombinant human CXCL10 has
this methionine at position 72 (PeproTech) and therefore has
TABLE I
Characterization of intact and furin cleaved CXCR3 targeting chemokines
Recombinant chemokines were treated with furin with or without carboxypeptidase B, and their masses were determined using MALDI-MS.
Theoretical masses for the furin-processed chemokines are only specified whenever the furin consensus sequence Arg-Xaa-(Lys/Arg)-Arg is present
within the primary structure of the chemokine. CXCL10 (R72M) refers to the CXCL10 molecule that has a methionine at position 72 instead of
an arginine and therefore lacks the furin consensus site.
Chemokine AAa
Theoretical mass (Da) Experimental mass (Da)
Intact Furin FurinCPBb Intact Furin FurinCPBb
Human
Met-CXCL10 78 8773.5 8589.3 8304.9 8773.8 8588.9 8305.5
CXCL10 (R72M) 77 8617.3 8617.5 8617.5
CXCL9 103 11721 11722 See Fig.5
CXCL11 73 8303.0 8303.6 8303.3
Mouse
Met-CXCL10 78 8828.6 8660.3 8376.0 8828.3 8660.3 8375.7
a AA, amino acids.
b CPB, carboxypeptidase B.
FIG. 2. In vitro cleavage of CXCL10
by furin and carboxypeptidase B. Re-
combinant human Met-CXCL10 (2 M)
was incubated for 3 h at 37 °C in the
presence or absence of different enzymes.
Samples were subsequently measured us-
ing MALDI-MS. A, untreated Met-
CXCL10. B, Met-CXCL10 incubated with
furin (5 units/ml). C, Met-CXCL10 incu-
bated with furin (5 units/ml)  car-
boxypeptidase B (0.5 units/ml). The C-ter-
minal amino acids of CXCL10 and the
cleavage site of the respective enzymes
are shown.
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the C-terminal sequence -Lys-Glu-Met-Ser-Lys-Arg-Ser-Pro.
Because this sequence does not comply with the furin consen-
sus sequence shown above, we predicted that this recombinant
human CXCL10 is not sensitive to furin cleavage. Upon treat-
ment of this mutant recombinant protein with furin, we indeed
found that it was not processed (Table I). This confirms that the
arginine at position 72 is essential for furin-mediated cleavage
of human CXCL10.
CXCL10 Production in Cytokine-stimulated Primary Fibro-
blasts—Unlike other pro-protein convertases, furin is widely ex-
pressed in different cells and tissues. To determine whether
processing of CXCL10 is keratinocyte specific or also occurs in
another cell type, we stimulated primary human dermal fibro-
blasts with IFN- and TNF- at concentrations that have previ-
ously been shown to highly induce mRNA levels of the CXCR3
targeting chemokines in these cells (28). Following heparin affin-
ity chromatography, chemokines were purified using reversed
phase chromatography (Fig. 4A). Mass spectrometric analysis of
a CXCL10-containing fraction (indicated with a bar in the chro-
matogram), showed that also in these cells CXCL10 was (par-
tially) processed to a molecule with a mass of 8173 Da (Fig. 4B),
corresponding to CXCL10-(1–73). In contrast to keratinocyte-
derived CXCL10, however, most of the fibroblast produced
CXCL10 was intact (1–77). In addition, masses corresponding to
N-terminally truncated CXCL10-(3–77) and CXCL10-(3–73)
were identified, most probably reflecting N-terminal processing
of CXCL10 by dipeptidylpeptidase IV.
In addition to CXCL10, we identified masses matching
CCL5-(1–68) and CCL5-(3–68) in this sample (Fig. 4B), the
latter most probably representing the dipeptidylpeptidase IV
processed form of CCL5 (20). The identity of CCL5 was con-
firmed by sequence analysis of a tryptic fragment of this pro-
tein (EYFYTSGK, amino acids 26–33 of CCL5). No masses
were identified that would match with furin-mediated cleavage
of CCL5, which is in agreement with the fact that CCL5 does
not contain a furin consensus sequence.
Furin-mediated Cleavage of Other CXCR3-targeting Chemo-
kines—In contrast to human CXCL10, human CXCL9 and -11
do not contain the furin consensus sequence Arg-Xaa-(Lys/
Arg)-Arg, although they contain many basic residues in their
C-terminal region. As it has been shown that also proteins
containing sequences that do not fully fit the consensus se-
quence can be substrates for furin, we also incubated 2 M
solution of recombinant human CXCL9 and -11 with 5 units/ml
furin at 37 °C for 3 h. This demonstrated that human CXCL11
is not a substrate for furin (Table I). On the other hand, human
CXCL9 was cleaved at five different positions in the C-terminal
part of the molecule, all after a basic amino acid residue (Fig.
5). Under identical conditions used for the complete processing
of human CXCL10 (Fig. 2), however, human CXCL9 was only
partially processed.
Close inspection of the protein sequence of CXCL10 from
species other than human showed that the furin consensus
sequence is highly conserved. Mouse CXCL10 for example,
contains the C-terminal furin consensus sequence (in bold)
Ser-Gln-Lys-Arg-Ser-Lys-Arg-Ala-Pro, suggesting it could
also be processed after the second dibasic site. In agreement
with this, we found that upon treatment with furin, the mass of
recombinant mouse Met-CXCL10 shifted from 8828 to 8660 Da
(Table I). This corresponds to the loss of the C-terminal amino
acids Ala-Pro. No other masses were identified in the mouse
CXCL10 treated with furin, showing that the other di-basic
sequence in the C terminus of this CXCL10 (see above) is not a
substrate for furin.
Activation of CXCR3—The ability of the novel CXCL10 var-
iant to activate CXCR3 was tested using three different bioas-
says. First, Met-CXCL10 stimulated GTP binding to G in
CXCR3-transfected CHO cells was determined using a GTPS
binding assay (Fig. 6A). This revealed that Met-CXCL10-(1–74)
retained full activity on CXCR3. Similar results were obtained
in Ca2 mobilization in CXCR3-transfected CHO cells (Fig. 6B)
and chemotaxis of primary human T-cells (Fig. 6C). Overall,
the above results show that the agonistic properties of Met-
CXCL10-(1–78) and -(1–74) for CXCR3 are similar, indicating
that the C-terminal part of CXCL10 is not essential for proper
CXCR3 activation.
FIG. 3. Kinetics of furin-mediated
cleavage in vitro. A, recombinant hu-
man CXCL10 (0.5 M) was incubated with
5 units/ml of furin at 37 °C for different
periods of time. MALDI-MS was used to
determine the relative amount of intact
CXCL10 (Met-CXCL10-(1–78)) and pro-
cessed CXCL10 (Met-CXCL10-(1–76)). B,
different concentration of recombinant
human CXCL10 (20 l) were incubated
with 5 units/ml of furin for 15 min.
MALDI-MS was used to determine the
relative amount of intact CXCL10 and
processed CXCL10. Data were fitted ac-
cording to Michaelis-Menten kinetics.
Furin-mediated Cleavage of CXCL1013406
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
FIG. 4. Purification and character-
ization of CXCL10 produced by pri-
mary human fibroblasts. Primary hu-
man fibroblasts were stimulated with
IFN (500 units/ml) and TNF (500 units/
ml) and allowed to excrete chemokines for
16 h. Following heparin affinity chroma-
tography of culture medium, chemokines
were purified using reversed phase chro-
matography (A). CXCL10-containing frac-
tions were measured using MALDI-MS
(B). Bar indicates fractions measured by
MALDI-MS.
FIG. 5. In vitro cleavage of human CXCL9 by furin. Recombinant human CXCL9 (2 M) was incubated with furin (5 units/ml) at 37 °C for
3 h. MALDI-MS was used to determine the different processed variants of CXCL9. The C terminus of CXCL9 is shown with the cleavage sites
indicated by capital letters.
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Inverse Agonism of ORF74—The genomes of several viruses
contain sequences that show a high similarity with chemokine
receptors. The Kaposi’s sarcoma associated herpes virus (hu-
man herpesvirus 8), for example, contains a gene (ORF74)
encoding a seven-transmembrane receptor that shows the
highest similarity with human CXCR1, 2 and 3. This viral
receptor shows a high level of constitutive activity, which is
most probably causally related to the pathogenesis of Kaposi’s
sarcoma (29).
Interestingly, CXCL10 has been shown to be an inverse
agonist on this receptor (30). Although the N-terminal amino
acids of CXCL10 have been shown to be essential for CXCR3
activation (31), this is not the case for the inhibitory effect on
the constitutive activity of ORF74 (30), indicating that other
determinants might be involved in this activity. Similarly, we
found that Met-CXCL10-(1–74) has still potent inverse agonis-
tic activities on ORF74 (Fig. 7).
Antibacterial Activity of CXCL10—It has recently been
shown that several chemokines, including the ligands for
CXCR3, show direct microbicidal activity (19, 32). Because it is
believed that the C-terminal region plays an essential role for
this activity, we determined the potency of intact and C-termi-
nally truncated CXCL10 in inhibiting the growth of E. coli and
L. monocytogenes, which revealed no apparent difference be-
tween the two CXCL10 variants (Fig. 8).
DISCUSSION
Chemokines comprise a class of more than 50 proteins that
control the migration and activation of leukocytes through
activation of their concomitant receptors. The complexity of
this system is not only controlled at the level of expression but
also as a result of post-translational processing. A limited num-
ber of studies have shown restricted truncation of chemokines.
It is at present well established that the endopeptidase
dipeptidylpeptidase IV (CD26) cleaves many chemokines hav-
ing a penultimate proline or alanine at the N terminus, includ-
ing the CXCR3 ligands (2, 22, 31). Recently, the N-terminal
region of chemokines has been shown to be sensitive to cleav-
age by matrix metalloproteinases (MMP). MMP-9- and MMP-
2-mediated cleavage of CCL7 and CXCL12, respectively, neg-
atively modulates their chemokine receptor-mediated activity
(3, 33) while CXCL8 is highly potentiated after cleavage by
MMP-9 (25). Other proteases involved in processing of chemo-
kines include cathepsins (4, 6), elastase (5) urokinase plasmin-
ogen activator, and plasmin (8).
In this study we have described furin as a novel chemokine-
modifying enzyme. Furin cleaves CXCL10 in vitro at a furin
consensus site, resulting in a CXCL10 molecule that is sensi-
tive to a basic amino acid-specific carboxypeptidase. Upon trim-
ming by such a carboxypeptidase in vitro, a CXCL10 molecule
is created that lacks the last four amino acids. This C-termi-
nally truncated CXCL10 molecule is also produced in vivo by
cytokine stimulated primary keratinocytes and fibroblasts. A
pro-protein convertase inhibitor, decanoyl-RVKR-chloromethyl-
ketone, prevents the production of this C-terminally truncated
CXCL10, indicating that furin is also involved in the in vivo
cleavage of CXCL10.
Furin belongs to the group of pro-protein convertases (PCs).
These enzymes are involved in the production of many biolog-
ically active proteins like e.g. growth factors, hormones, recep-
tors, and matrix metalloproteinases (26, 34). In general, these
FIG. 6. CXCR3 activating potency of CXCL10 variants. Full-
length (Met-CXCL10-(1–78) and C-terminally truncated CXCL10 (Met-
CXCL10-(1–74) were tested for their activity on CXCR3. A, GTPS
binding in CXCR3-transfected CHO cells. B, Ca2 mobilization in
CXCR3-transfected CHO cells loaded with Fura-2. C, chemotaxis of
PHA and IL-2 expanded primary human T-cells. For the experiments
with CHO cells, a representative experiment of three is shown. Chemo-
taxis experiments were performed with T-cells from three different
donors.
FIG. 7. Inverse agonism activity of CXCL10 on ORF74. COS-7
cells were transiently transfected with a cDNA encoding the HHV-8
encoded ORF74. Cells were incubated with different concentrations of
full-length CXCL10 (Met-CXCL10-(1–78) and C-terminally truncated
CXCL10 (Met-CXCL10-(1–74). After 48 h, NF-B-driven luciferase ex-
pression was measured. A representative experiment performed in
triplicate is shown, and the experiment was repeated two times.
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active proteins result from limited processing at paired basic
residues within higher molecular mass precursors. In the case
of neuropeptides, proteolysis often occurs in secretory vesicles
that are secreted upon the proper stimulus. The expression of
furin is found in the trans-Golgi network of many cells and
tissues and plays a role in the processing of precursors for
constitutively secreted proteins. Some PCs are specific for cer-
tain cells and tissues. In the epidermis, expression of furin,
PACE4, PC5/6, and PC7/8 has been identified (35). Because the
pro-protein convertase inhibitor used in our studies also inhib-
its other PCs, we cannot exclude the possibility that other PCs
are involved in the CXCL10 processing in vivo.
Human and murine CXCL10 (but also e.g. hamster, rat,
sheep, goat, and monkey) contain the furin consensus sequence
Arg4-Xaa-Lys2-Arg1, and we demonstrated that both are
processed by furin. In a survey of the primary structures of
other human chemokines we found no perfect match with a
furin consensus sequence in the C-terminal region. Our results
with the in vitro processing of human CXCL9 however showed,
that also sequences that do not fully comply with the consensus
sequence are potential furin cleavage sites, though only partial
processing was observed. Consequently, more chemokines than
solely predicted on this consensus sequence may be substrates
for furin in vitro. Using cytokine-stimulated keratinocytes, we
only detected full-length CXCL9 (22) and did not find evidence
for furin-mediated processing of CXCL9 in vivo. Others have
found C-terminal truncations of CXCL9 (36) and although the
mechanism by which these are formed is unknown, it most
likely does not reflect furin-mediated cleavage.
In the case of CXCL9, furin cleavage in vitro was most
efficient at paired basic residues. Interestingly, cleavage also
occurred after lysine residues, although site-directed mutagen-
esis experiment with several substrates and structural analy-
sis of furin suggested that an arginine at this position is essen-
tial (26, 37). A basic amino acid at position 4 is also favorable
for furin-mediated cleavage. In the case of human CXCL10, the
importance of this residue is underscored by the observation
that the mutant CXCL10 with the Arg to Met substitution at
this position was not cleaved by furin in vitro (Table I). More-
over, mouse CXCL10 contains two pairs of dibasic residues in
the C-terminal part of the protein, with Lys71-Arg72 not having
a basic residue at position 4. This dibasic sequence was in-
sensitive to furin cleavage in vitro, while the Lys74-Arg75 was
fully processed (Table I).
The fact that only 40% of CXCL10 from cytokine-stimu-
lated keratinocytes is processed indicates that the activity of
furin in these cells is limited. In contrast, the fact that we have
never identified a native CXCL10 molecule corresponding to
CXCL10-(1–75) indicates that the trimming of the basic resi-
dues by a carboxypeptidase is not a rate-limiting step in vivo. The
cleavage of CXCL10 by furin seems to be very efficient as the Km
(5 M) is much lower then identified for other substrates (38).
In contrast to the N-terminal truncations, there are only a
few examples of natural occurring C-terminal truncations of
chemokines having effect on chemokine receptor activation. In
general, the N terminus and the N-loop are considered to form
the most important chemokine binding and activation domains
(39). An exception to this rule is CXCL7, for which a more
potent CXCR2 agonist was identified after cleavage of several
C-terminal amino acids by an as yet unknown mechanism (11).
In the case of CXCL10, full activity on CXCR3 was found for
the C-terminally truncated variant (Fig. 6). This indicates that
furin-mediated processing of CXCL10 does not impair nor en-
hance the activity on CXCR3. This is in concordance with
recent data on the interaction of CXCL10 with its receptor.
Mutational analysis studies have focused on specific residues
in CXCL10 that are important in the CXCR3 activating activity
of CXCL10 (40). Among others, especially the arginine at posi-
tion 8 was shown to be very important.
Another G-protein-coupled receptor with CXCL10 binding
properties is encoded by the Kaposi’s-associated human herpes
virus 8. This receptor displays a high level of constitutive
activity (41), which appears an important determinant in the
pathogenesis of Kaposi’s sarcoma. Although several chemo-
kines (e.g. CXCL1) are agonists for this receptor, CXCL10 has
been shown to be a potent inverse agonist (30). In this case, the
N terminus of CXCL10 has been shown to be of minor impor-
tance (30) and our studies have now shown that also the C-
terminal four amino acids are not essential for this inverse
agonistic activity.
FIG. 8. Antibacterial activity of
CXCL10. The antibacterial activity of
full-length CXCL10 (Met-CXCL10-(1–
78)) and C-terminally truncated (Met
CXCL10-(1–74)) was tested on L. monocy-
togeneses (upper part) and E. coli (lower
part) using a radial diffusion assay. For
this purpose, within solidified agar con-
taining the representative bacteria, 3-mm
wells were punched and filled with 5 l of
chemokine solution. Antimicrobial activ-
ity was determined as a clear zone around
the well after 16-h incubation at 37 °C,
and are represented in radial diffusion
units: (diameter of clear zone in millime-
ters  well diameter)  10. A represent-
ative experiment of three is shown. RDU,
radial diffusion units.
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Some chemokines possess activities that are not mediated
through G-protein-coupled receptor activation. It has for exam-
ple recently become apparent that certain chemokines possess
a direct antibacterial activity, pointing to the fact that these
proteins play a role in both the innate and acquired immunity.
Similar dual activities have also been assigned to a group of
peptides, the -defensins, which were at first defined as anti-
bacterial proteins (42). Several overlapping structural domains
between chemokines and defensins have been implicated in
their common antibacterial activity, which showed that espe-
cially the -helix is of major importance (32). Fascinatingly, in
the case of CXCL7, a yet undefined mechanism in platelets can
release the last two C-terminal amino acids resulting in a very
potent antibacterial protein, previously known as the throm-
bocidins. This points to an essential role of the C terminus in
the microbicidal activity of this chemokine (10). Direct antibac-
terial activity for the CXCR3-targeting chemokines has only
recently been recognized (19). In contrast to the results with
CXCL7, deletion of amino acid residues at the C terminus of
CXCL10 does not alter its antibacterial activity toward E. coli
and L. monocytogeneses.
Because the stretches of basic amino acids in the C terminus
of chemokines are generally believed to be involved in the
affinity for heparin, one possibility could be that the truncated
CXCL10, that has lost two basic amino acids, has altered
heparin binding affinities. Recent studies performed with a
large set of CXCL10 mutants however, suggests that the last
four amino acids are not essential for heparin binding (40).
Moreover, in our own chemokine purification procedure we
have also applied salt gradients to elute chemokines from the
heparin affinity column. In these cases, both CXCL10 variants
always co-eluted (data not shown).
Truncated CXCL10 might have an altered affinity for the
recently described CXCR3B receptor (43), which is implicated
in the angiogenic activities of the CXCR3 ligands. However,
CXCR3B differs from CXCR3 only in its N-terminal part and as
this region is probably only involved in recognizing the N
terminus of the ligands this possibility seems less plausible.
Moreover, genomic data from the CXCR3 locus in mouse indi-
cates that there is no CXCR3B in this species and therefore a
similar mechanism, expected for the conserved processing site,
would be absent in this species.
Since all ligands for CXCR3 are natural antagonists for
CCR3 (44), truncated CXCL10 might have an increased or
impaired affinity for CCR3.
Finally, truncated CXCL10 might affect hitherto unexpected
biological responses like recently shown for CXCL12, where
MMP-2-mediated cleavage gives rise to a highly neurotoxic
variant implicated in (CXCR4-independent) neurodegenera-
tion (9). Interestingly, there is evidence for a CXCL10 receptor
that is not CXCR3 on a set of different cell lines (45). Its cloning
and characterization would open the possibility to study the
role of the C-terminally processed CXCL10 in activating this
novel receptor.
In conclusion, we have identified furin as a novel chemokine-
modifying enzyme in vitro and most probably also in vivo. This
conversion generates a CXCL10 variant that retains full ago-
nistic activity for CXCR3, inverse agonistic activities on ORF74
and antibacterial properties toward E. coli and L. monocyto-
genes. The biological significance of furin-mediated CXCL10
truncation is as yet not elucidated. The high conservation of the
furin consensus site in CXCL10 from different species implies
a specific function for furin-processed CXCL10.
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